SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Silence Therapeutics plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$19.58+10.90 (+125.58%)
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
24M
Shares held, 13F filers
Institutional holders
72
20 new, 4 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Raymond Debbane | 9,934,314 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| Tetragon Financial Management LP | 9,878,565 | 5.30% | 13G (passive) amendment | Oct 5, 2026 |
| Reade E. Griffith | 9,708,153 | 5.20% | 13G (passive) | Oct 5, 2026 |
| Invus Public Equities, L.P. | 9,000,000 | 7.80% | 13G (passive) amendment | Dec 31, 2023 |
| Jeremy C. Green | 7,197,951 | 5.10% | 13G (passive) | Dec 31, 2024 |
| Richard Ian Griffiths | 34,543,302 | 24.40% | 13D (active) amendment | Jun 25, 2025 |
| Richard Griffiths | 14,391,498 | 7.97% | 13D (active) amendment | Aug 12, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SLN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Siren, L.L.C. | 3,311,438 | – | $36.36M | +400,000 | 0.74% |
| TCG Crossover Management, LLC | 3,033,560 | – | $33.31M | – | 0.80% |
| Nantahala Capital Management, LLC | 2,693,462 | – | $29.57M | +546,731 | 0.49% |
| Redmile Group, LLC | 2,164,777 | – | $23.77M | – | 1.60% |
| Citadel Advisors LLC | 1,329,625 | – | $14.60M | +94,818 | 0.00% |
| Nextech Invest, Ltd. | 952,400 | – | $10.46M | – | 0.50% |
| Millennium Management LLC | 909,279 | – | $9.98M | −164,912 | 0.00% |
| Ikarian Capital, LLC | 830,784 | – | $1.83M | −35,000 | 0.20% |
| TFG Asset Management GP Ltd | 764,256 | – | $8.39M | +134,095 | 1.32% |
| Soleus Capital Management, L.P. | 630,000 | – | $6.92M | New | 0.24% |
| Balyasny Asset Management L.P. | 610,980 | – | $6.71M | New | 0.01% |
| 5AM Venture Management, LLC | 476,200 | – | $5.23M | – | 1.82% |
| Great Point Partners LLC | 450,000 | – | $4.94M | −570,489 | 0.93% |
| Morgan Stanley | 403,172 | – | $4.43M | +337,686 | 0.00% |
| Ameriprise Financial Inc | 370,052 | – | $4.06M | New | 0.00% |
| Jane Street Group, LLC | 369,151 | – | $4.05M | +268,224 | 0.00% |
| ADAR1 Capital Management, LLC | 338,373 | – | $3.72M | +166,216 | 0.17% |
| SummitTX Capital, L.P. | 326,648 | – | $3.59M | New | 0.09% |
| Schonfeld Strategic Advisors LLC | 269,348 | – | $2.96M | New | 0.01% |
| UBS Group AG | 243,152 | – | $2.67M | −3,785 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 24M | 20 / 22 | 18 / 4 | 5M | 2M |
| Q1 2026 | 56 | 20M | 6 / 24 | 11 / 7 | 4M | 2M |
| Q4 2025 | 58 | 18M | 14 / 15 | 17 / 10 | 3M | 5M |
| Q3 2025 | 54 | 20M | 6 / 15 | 16 / 7 | 0M | 0M |
| Q2 2025 | 55 | 20M | 9 / 13 | 18 / 13 | 1M | 3M |
| Q1 2025 | 59 | 22M | 6 / 18 | 25 / 11 | 2M | 4M |
| Q4 2024 | 65 | 25M | 16 / 24 | 13 / 20 | 5M | 8M |
| Q3 2024 | 69 | 28M | 13 / 24 | 16 / 15 | 8M | 9M |
| Q2 2024 | 71 | 29M | 12 / 23 | 20 / 5 | 5M | 4M |
| Q1 2024 | 64 | 28M | 32 / 17 | 11 / 2 | 13M | 6M |
| Q4 2023 | 34 | 21M | 8 / 9 | 6 / 2 | 2M | 1M |
| Q3 2023 | 28 | 20M | 4 / 4 | 7 / 5 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SLN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Advisor Biotechnology Fund | 482,088 | – | $5.06M | 0.23% | Jul 31, 2026 |
| iShares Biotechnology ETF | 185,777 | – | $2.04M | 0.02% | Jun 30, 2026 |
| Alger Small Cap Growth Fund | 105,679 | – | $1.11M | 0.54% | Jul 31, 2026 |
| Alger Small Cap Growth Institutional Fund | 41,292 | – | $433.15K | 0.54% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 29,538 | – | $203.81K | 0.00% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF | 9,532 | – | $104.66K | 0.01% | Jun 30, 2026 |
| ActivePassive International Equity ETF | 8,695 | – | $60.00K | 0.01% | May 31, 2026 |
| Steward Values Enhanced International Fund | 5,800 | – | $60.84K | 0.02% | Jul 31, 2026 |
| Invesco Nasdaq Biotechnology ETF | 2,476 | – | $17.08K | 0.03% | May 31, 2026 |
| ProShares Ultra Nasdaq Biotechnology | 1,736 | – | $11.98K | 0.02% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 1,000 | – | $10.98K | 0.00% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 24 | – | $264 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Rhonda Lynette Hellums | Chief Financial Officer, Director | 1,500 | Jan 6, 2026 |
| Iain Ross | Interim PEO, Director | 39,942 | Dec 22, 2025 |
| Craig A. Tooman | President and CEO, Director | 33,486 | Jan 6, 2025 |
| Steven J. Romano | EVP and Chief R&D Officer | 12,993 | Jan 6, 2026 |
| James Ede-Golightly | Director | 15,000 | Jan 6, 2026 |
| Timothy McInerney | Director | – | Jan 6, 2026 |
| David Lemus | Director | 7,527 | Jan 6, 2026 |
| Michael H. Davidson | Director | 12,993 | Jan 6, 2025 |
| Richard Ian Griffiths | 10% owner | – | Aug 13, 2026 |